LY 3337641

Drug Profile

LY 3337641

Alternative Names: LY3337641

Latest Information Update: 15 Dec 2015

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antirheumatics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Rheumatoid arthritis

Most Recent Events

  • 15 Dec 2015 Eli Lilly plans to initiate the phase II RAjuvenate trial for Rheumatoid arthritis (Treatment-experienced) in Argentina, Australia, Austria, Germany, Italy, South Korea, Mexico, Poland, Slovakia, South Africa, Spain and USA (PO) (NCT02628028)
  • 01 Dec 2015 Preclinical trials in Rheumatoid arthritis in USA (PO) before December 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top